Absorption, Biliary Excretion, and Metabolism of a New Cholelitholytic Agent, Ursodeoxycholyl N-Carboxymethylglycine and Its Esters in Rats

  • HATONO Shunso
    Wakunaga Pharmaceutical Co., Ltd. Institute of Pharmaceutical Sciences, Hiroshima University School of Medicine
  • YOSHIDA Harumi
    Wakunaga Pharmaceutical Co., Ltd. Institute of Pharmaceutical Sciences, Hiroshima University School of Medicine
  • MATSUNAMI Masumi
    Wakunaga Pharmaceutical Co., Ltd. Institute of Pharmaceutical Sciences, Hiroshima University School of Medicine
  • IDE Yukako
    Wakunaga Pharmaceutical Co., Ltd. Institute of Pharmaceutical Sciences, Hiroshima University School of Medicine
  • MATSUDA Kaoru
    Wakunaga Pharmaceutical Co., Ltd. Institute of Pharmaceutical Sciences, Hiroshima University School of Medicine
  • YATSUNAMI Takashi
    Wakunaga Pharmaceutical Co., Ltd. Institute of Pharmaceutical Sciences, Hiroshima University School of Medicine
  • FUWA Tohru
    Wakunaga Pharmaceutical Co., Ltd. Institute of Pharmaceutical Sciences, Hiroshima University School of Medicine
  • KIHIRA Kenji
    Wakunaga Pharmaceutical Co., Ltd. Institute of Pharmaceutical Sciences, Hiroshima University School of Medicine
  • KURAMOTO Taiju
    Wakunaga Pharmaceutical Co., Ltd. Institute of Pharmaceutical Sciences, Hiroshima University School of Medicine
  • HOSHITA Takahiko
    Wakunaga Pharmaceutical Co., Ltd. Institute of Pharmaceutical Sciences, Hiroshima University School of Medicine

この論文をさがす

抄録

Intestinal absorption, biliary excretion and metabolism of a calcium gallstone dissolving agent, [11,12-^3H] ursodeoxycholyl-N-carboxymethylglycine (UDC-CMG) and its monoethyl, diethyl and dipivaloyloxyethyl esters (UDC-CMG-Et, UDC-CMG-Et_2 and UDC-CMG-PV_2) were studied in bile duct cannulated rats. Biliary recovery of [^3H]-labeled UDC-CMG, UDC-CMG-Et and UDC-CMG-Et_2 after intraduodenal administration were 65%, 80%, 98%, respectively. Radio-thin layer chromatography analysis of the bile revealed that UDC-CMG didn't undergo any biotransformation during administration and excretion. About 80% and 20% of radioactivity recovered in the bile was identified as UDC-CMG-Et and UDC-CMG, respectively, after intraduodenal administrations of [^3H] UDC-CMG-Et_2 and [^3H] UDC-CMG-Et. The administered intact UDC-CMG-Et_2 was not found in the bile. Intraduodenally administered [^3H] UDC-CMG-PV_2 was rapidly recovered in the bile. The total recovery rate was 78% within a 24 h period. More than 80% of the radioactivity recovered in the bile was found as UDC-CMG. Lesser amounts of the monopivaloyloxyethyl ester of UDC-CMG were also found, but intact UDC-CMG-PV_2 was not detected in the bile as in the case of UDC-CMG-Et_2. Among the esters of UDC-CMG investigated in the present studies, only UDC-CMG-PV_2 was excreted in the bile mainly as the perhydrolyzed form, UDC-CMG. These results suggest the usefulness of UDC-CMG-PV_2 as the pro-drug in calcium gallstone dissolution therapy.

収録刊行物

キーワード

詳細情報 詳細情報について

問題の指摘

ページトップへ